APOE and Alzheimer disease: In the clinically diagnosed AD cohort, an elevated P-tau181 concentration was observed in APOE ε4-positive carriers (medianAPOE4+  = 75 pg/mL) compared with APOE ε4-negative carriers (medianAPOE4- = 62, P = 0.028) (Additional file 1: Table 4).